Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries
The results of this study highlighted significant variations in the acceptance of non-traditional trial designs by HTA bodies across Europe. Actions are needed to facilitate a more progressive view on non-traditional clinical trial designs to ensure fast patient access to highly innovative treatments.
Authors
- Mickaël Hiligsmann (ORCID: https://orcid.org/0000-0003-4274-9258)
- L.M. Maas (ORCID: https://orcid.org/0000-0002-0032-0712)
- Angelika Joos (ORCID: https://orcid.org/0000-0001-9585-265X)
- Inkatuuli Heikkinen (ORCID: https://orcid.org/0000-0002-0916-4189)
- E. Reith
- M. De Iaco
Institutions
- Maastricht University (NL)
- Lundbeck (Germany) (DE)
- Global Policy Institute (US)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1080/14737167.2025.2530622
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00